亚洲精品成人免费_91女神娇喘疯狂3p之夜_精品韩国一级久久_av毛片网_www超碰com_午夜视频体内射.COM.COM

加拿大Resverlogix  
Resverlogix Corp. (TSX: RVX) 是一家心血管疾病臨床研究公司，公司擁有能夠調(diào)節(jié)蛋白質(zhì)形成的表觀遺傳學(xué)平臺(tái)技術(shù)。Resverlogix 正在開(kāi)發(fā) RVX-208——用于治療動(dòng)脈粥樣硬化的同類(lèi)首個(gè)小分子。RVX-208 是首個(gè)正在進(jìn)行臨床試驗(yàn)的 BET 溴區(qū)結(jié)構(gòu)域抑制劑。出自 Resverlogix 表觀遺傳學(xué)藥物發(fā)現(xiàn)平臺(tái)的新復(fù)合制劑通過(guò)抑制 BET 溴區(qū)結(jié)構(gòu)域而發(fā)揮作用，并有希望用來(lái)治療癌癥、自身免疫性疾病和神經(jīng)退行性疾病等多種病癥。Resverlogix 的普通股在多倫多證券交易所交易 (TSX: RVX)。

Resverlogix Corp. is a publicly traded biotechnology company (TSX:RVX) engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas? Plaque Regression program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I production. These vital therapies are focused to address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Alzheimer's disease, Peripheral Artery Disease and Autoimmune diseases.

Our Business Model is to seek strategic opportunities through early alliance partnerships that are best suited to bring our technology platforms to successful commercialization. We are committed to good corporate governance and protection of shareholder value.